This study is in progress, not accepting new patients
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Summary
- Eligibility
- for people ages 1-25 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Benjamin Huang
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Benjamin Huang
Dr. Benjamin Huang is a physician-scientist whose research program focuses on mouse cancer modeling, molecular therapeutics, and functional genomics.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT03876769
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- About 121 people participating
- Last Updated